A Phase 2b, Randomized, Double-Blind, Multicenter, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Treprostinil Palmitil Inhalation Powder in Participants With Pulmonary Arterial Hypertension
Latest Information Update: 10 Nov 2025
At a glance
- Drugs Treprostinil palmitil (Primary)
- Indications Pulmonary arterial hypertension
- Focus Therapeutic Use
- Sponsors Insmed
Most Recent Events
- 22 Sep 2025 According to an Insmed media release, data from this study will be presented in European Respiratory Society (ERS) 2025 Congress's "Abstracts Leading to Evolution in Respiratory Medicine Trials (ALERT)" session- being held September 27 - October 1, 2025, in Amsterdam.
- 10 Jun 2025 Primary endpoint (Change from Baseline in Pulmonary Vascular Resistance at Week 16) has been met.
- 10 Jun 2025 Results presented in the Insmed Media Release